Chris Leiske

Title: Chris Leiske - Innovator in Antibody Conjugation Technology

Introduction

Chris Leiske is a notable inventor based in Bothell, WA (US). He has made significant contributions to the field of biotechnology, particularly in the development of modified antibodies for therapeutic applications. His innovative work has led to the creation of a patent that enhances the efficacy of antibody-drug conjugates.

Latest Patents

Chris Leiske holds a patent titled "Cysteine mutated antibodies for conjugation." This invention provides modified heavy chain constant regions that include a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues create sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody, allowing a stoichiometry of one molecule of antibody to four of drug or label. The selection of the cysteine at position 295, with or without cysteine at position 239, is advantageous over cysteines at many other positions due to ease of expression, stability, and reduced cytotoxicity. Chris Leiske has 1 patent to his name.

Career Highlights

Chris is currently employed at Seagen Inc., a leading biotechnology company focused on developing innovative therapies for cancer treatment. His work at Seagen has positioned him as a key player in the advancement of antibody-drug conjugate technology.

Collaborations

Throughout his career, Chris has collaborated with talented professionals, including Andrew Waight and Travis Biechele. These collaborations have fostered a productive environment for innovation and development in the field of biotechnology.

Conclusion

Chris Leiske's contributions to antibody conjugation technology exemplify the impact of innovative thinking in biotechnology. His patent on cysteine mutated antibodies showcases his commitment to advancing therapeutic options for patients.